The participants of the expert round table discussing biological enamel regeneration define the therapy with Curodont™ Repair as Guided Enamel Regeneration – analogous to Guided Tissue Regeneration in periodontology.
Guided Enamel Regeneration with Curodont™ Repair enables the growth of mineralised tissue within the enclosed space of an early carious lesion. The growing tissue is protected against external influences by the mineralised surface layer – similar to the membrane used during Guided Tissue Regeneration protecting growth of new periodontal tissue.
The full report covering the expert discussion with among others Professors Kunzelmann, Saxer and Splieth includes the therapy model for caries proposed by the experts. The report was published in the latest edition of the Dental Journal Schweiz.
About Curodont™ and the Curolox® Technology
The patented Curolox® Technology is based on peptides self-assembling into a 3-dimensional matrix, triggering biomimetic mineralisation and repair. The core technology is the basis for all innovative credentis products.
CURODONT™ REPAIR provides dentists with a non-invasive option for natural in-depth mineralisation which allows the regeneration of caries lesions and similar defects. Applied to an early lesion, CURODONT™ REPAIR forms a scaffold within the lesion to guide new hydroxyapatite (tooth mineral) crystals to form and grow. Ideally, the caries is stopped and the lesion will mineralise within several weeks.
CURODONT™ PROTECT uses the Curolox® Technology to protect the tooth surface from acid attack. CURODONT™ D’SENZ is optimised for the treatment of dentine hypersensitivity, to be used before dental hygiene treatment or in conjunction with tooth bleaching.
With its regenerative product line, credentis supports the trend towards prevention and early treatment. The ultimate goal is to prevent caries through the use of its regenerative solutions and frequent recalls by dentists and hygienists.
About credentis ag
credentis ag is headquartered in the Technopark Aargau, Switzerland. credentis has won multiple awards as well as support from organizations such as Genilem. Public grants include Swiss National Science Foundation (SNSF), Aargauer Forschungsfonds in collaboration with the FHNW School of Life Sciences in Muttenz and the Medical Technologies IKC (in co-operation with the University of Leeds).
Dr. Dominik Lysek, CEO and Michael Hug, CTO have a strong track record in science, development and medical technology, with focus in the dental industry. credentis board members Dr. Werner Berner, Dr. Michael Peetz, Gerard Moufflet and Dr. Erich Platzer (chairman), contribute their pharma, medtech and dental industry expertise.
Help employers find you! Check out all the jobs and post your resume.
Guided Enamel Regeneration with Curodont™ Repair enables the growth of mineralised tissue within the enclosed space of an early carious lesion. The growing tissue is protected against external influences by the mineralised surface layer – similar to the membrane used during Guided Tissue Regeneration protecting growth of new periodontal tissue.
The full report covering the expert discussion with among others Professors Kunzelmann, Saxer and Splieth includes the therapy model for caries proposed by the experts. The report was published in the latest edition of the Dental Journal Schweiz.
About Curodont™ and the Curolox® Technology
The patented Curolox® Technology is based on peptides self-assembling into a 3-dimensional matrix, triggering biomimetic mineralisation and repair. The core technology is the basis for all innovative credentis products.
CURODONT™ REPAIR provides dentists with a non-invasive option for natural in-depth mineralisation which allows the regeneration of caries lesions and similar defects. Applied to an early lesion, CURODONT™ REPAIR forms a scaffold within the lesion to guide new hydroxyapatite (tooth mineral) crystals to form and grow. Ideally, the caries is stopped and the lesion will mineralise within several weeks.
CURODONT™ PROTECT uses the Curolox® Technology to protect the tooth surface from acid attack. CURODONT™ D’SENZ is optimised for the treatment of dentine hypersensitivity, to be used before dental hygiene treatment or in conjunction with tooth bleaching.
With its regenerative product line, credentis supports the trend towards prevention and early treatment. The ultimate goal is to prevent caries through the use of its regenerative solutions and frequent recalls by dentists and hygienists.
About credentis ag
credentis ag is headquartered in the Technopark Aargau, Switzerland. credentis has won multiple awards as well as support from organizations such as Genilem. Public grants include Swiss National Science Foundation (SNSF), Aargauer Forschungsfonds in collaboration with the FHNW School of Life Sciences in Muttenz and the Medical Technologies IKC (in co-operation with the University of Leeds).
Dr. Dominik Lysek, CEO and Michael Hug, CTO have a strong track record in science, development and medical technology, with focus in the dental industry. credentis board members Dr. Werner Berner, Dr. Michael Peetz, Gerard Moufflet and Dr. Erich Platzer (chairman), contribute their pharma, medtech and dental industry expertise.
Help employers find you! Check out all the jobs and post your resume.
